^
    2d
    Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Ipsen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Cabometyx (cabozantinib tablet)
    4d
    Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=28, Terminated, John Rieth | Trial completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Terminated; Study was terminated early due to changes in the treatment of melanoma
    Trial completion date • Trial termination
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    7d
    Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA. (PubMed, Discov Oncol)
    Through integrated multi-omics analysis, we established that oxidative stress pathways may drive pNET progression through a coordinated mechanism involving metabolic reprogramming (via BCL2L1 and PHGDH downregulation), immune microenvironment remodeling (through altered dendritic cell and NK cell function), and complex regulatory networks. BCL2L1 and PHGDH represent potential diagnostic biomarkers and candidate therapeutic targets that require experimental validation, providing new directions for precision medicine in pNET.
    Journal
    |
    BCL2L1 (BCL2-like 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • KCNQ1OT1 (KCNQ1 Opposite Strand/Antisense Transcript 1) • PHGDH (Phosphoglycerate Dehydrogenase) • MIR15A (MicroRNA 15a)
    |
    Cabometyx (cabozantinib tablet)
    8d
    Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches. (PubMed, JTO Clin Res Rep)
    The benefit of adjuvant therapy in well-differentiated tumors is unclear, whereas thymic neuroendocrine carcinomas often require multimodal approaches, including platinum-etoposide chemotherapy and radiotherapy...Somatostatin analogues are widely used in indolent or peptide receptor-positive tumors, whereas everolimus and, more recently, cabozantinib represent options for progressive disease...Despite promising therapeutic options, robust prospective data remain limited. The integration of TNENs into basket trials, the molecular refinement of prognostic subgroups (e.g., NET G3), and the conduct of dedicated multicenter prospective studies are urgently needed to define optimal treatment algorithms and improve clinical outcomes in these rare entities.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    everolimus • Cabometyx (cabozantinib tablet) • etoposide IV
    10d
    Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Emory University | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    10d
    Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov)
    P1, N=32, Recruiting, Emory University | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Padcev (enfortumab vedotin-ejfv)
    11d
    A091902: Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=89, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2026 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • paclitaxel • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    12d
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=99, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    12d
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    12d
    First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma. (PubMed, Cancer Chemother Pharmacol)
    This review consolidates 2023-2025 advances: phase III validation in post-IO/TKI ccRCC (progression-free survival and response-rate gains vs. everolimus), durable first-line activity with cabozantinib, and approval for advanced pheochromocytoma/paraganglioma-including patients ≥ 12 years-extending impact to endocrine and pediatric oncology...Caution is appropriate: overall survival benefit in randomized RCC trials is not yet demonstrated, resistance can emerge, and long-term hematologic and pulmonary effects require surveillance. Together, HIF-2α inhibition establishes a new, clinically actionable axis in GU oncology.
    Review • Journal • IO biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • EPAS1 (Endothelial PAS domain protein 1)
    |
    everolimus • Cabometyx (cabozantinib tablet) • Welireg (belzutifan)
    12d
    CAMILLA: Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (clinicaltrials.gov)
    P1/2, N=117, Recruiting, Anwaar Saeed | Trial completion date: Jan 2028 --> Jun 2029 | Trial primary completion date: Jan 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    RAS wild-type
    |
    Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)
    13d
    Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (clinicaltrials.gov)
    P2, N=200, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)